Academic Journals Database
Disseminating quality controlled scientific knowledge

Positions of calcium channel blocker lercanidipine according to evidence based cardiology

ADD TO MY LIST
 
Author(s): Yu.V. Lukina | S.Yu. Martsevich

Journal: Racionalʹnaâ Farmakoterapiâ v Kardiologii
ISSN 1819-6446

Volume: 6;
Issue: 4;
Start page: 558;
Date: 2010;
Original page

Keywords: lercanidipine | calcium channel blockers | randomized clinical trials | arterial hypertension.

ABSTRACT
Data of evidence based cardiology including results of international clinical trials on efficacy and safety of the modern calcium channel blocker (CCB), lercanidipine, are presented. Results of these trials show the firm position of lercanidipine in the modern cardiology and confirm that treatment with lercanidipine leads to significant reduction of systolic and diastolic blood pressure (BP) with no effect on heart rate (HR). Peripheral edema (the common side effect of CCBs) occurs rarer with lercanidipine treatment than this with any other CCB treatment. Lercanidipine can be recommended to patients with concomitant diseases due to its additional features.
Affiliate Program      Why do you need a reservation system?